|
|
| Product Name: | ML-180 | | Synonyms: | ML-180;SR1848;6-[4-(3-chlorophenyl)piperazin-1-yl]-3-cyclohexyl-1H-pyrimidine-2,4-dione;2,4(1H,3H)-Pyrimidinedione, 6-[4-(3-chlorophenyl)-1-piperazinyl]-3-cyclohexyl-;6-(4-(3-chlorophenyl)piperazin-1-yl)-3-cyclohexylpyrimidine-2,4(1H,3H)-dione;SR1848 >=98% (HPLC);ML-180 (SR1848);6-[4-(3-Chlorophenyl)piperazin-1-yl]-3-cyclohexylpyrimidine- ,4(1H,3H)dione | | CAS: | 863588-32-3 | | MF: | C20H25ClN4O2 | | MW: | 388.89 | | EINECS: | | | Product Categories: | | | Mol File: | 863588-32-3.mol |  |
| | ML-180 Chemical Properties |
| density | 1.312±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: 10 mg/ml | | form | A crystalline solid | | pka | 9.37±0.40(Predicted) | | color | Off-white to light yellow |
| | ML-180 Usage And Synthesis |
| Description | ML-180 is an inverse agonist of liver receptor homolog-1 (LRH-1, IC50 = 3.7 μM) with maximum efficacy of 64% repression. It is inactive at the related steroidogenic factor-1 transcriptional activator. Through LRH-1, ML-180 alters the expression of haptoglobin and serum amyloid proteins A1 and A4, induces the death of estrogen-receptor negative MDA-MB-231 breast cancer cells, and inhibits the steroidogenic acute regulatory promoter (IC50 = 2.05 μM). | | Definition | ChEBI: 6-[4-(3-chlorophenyl)-1-piperazinyl]-3-cyclohexyl-1H-pyrimidine-2,4-dione is a member of piperazines. |
| | ML-180 Preparation Products And Raw materials |
|